Synthetic Osteoconductive Scaffold — Magnus Veritas Medical Technologies (MVMT)

03 / Synthetic Osteoconductive Scaffold

A structure for new bone to grow through.

A hyper-crosslinked carbohydrate polymer originally developed as a substrate for stem cell culture and differentiation, now doing that same work inside the graft site. It optimizes the cellular microenvironment for bone formation and supports blood vessel ingrowth, so what fills the defect is vascularized, healthy bone rather than inert filler. Degradation is tuned to match the rate of regeneration, and because it starts radiolucent and turns radiopaque as fusion progresses, surgeons can watch the fusion happen instead of inferring it months later. Fully synthesized, so quality is consistent lot to lot with zero risk of disease transmission. Expands back to volume after compression, trimmable, stores at room temperature, and available in block, granulate, and cube forms — or custom shapes on request.

In a peer-reviewed retrospective study of 63 spinal fusion procedures, the polymer achieved a 91.8% overall fusion rate: 100% thoracic, 95% lumbar, and 85% cervical. Regions fused with it showed visible osseous formation within three months postoperatively and efficacy comparable to other bone graft substitutes at six months. Used as the sole bone graft substitute in a 29-patient subset, the fusion rate was 86.2%. No adverse events related to its use were observed. A separate ovine model showed bone growth equivalent to autograft on CT at six months with no histologic abnormalities. A separate retrospective cervical study reported fusion rates exceeding 90% by three months, comparable to i-Factor and autograft at 12 and 24 months.

91.8%

Fusion across 63 procedures, all spinal levels

95%

Lumbar fusion rate · 100% thoracic

3 mo

Visible osseous formation postoperatively

Mechanism: hyper-crosslinked carbohydrate polymer · FDA 510(k) K170165 · Peer-reviewed clinical + ovine data

Beyond Spine

Where else it has been used.

Critical-size bone defect repair

In a rabbit model of bilateral critical-sized femoral condyle defects, the polymer was compared against autologous bone and PLGA/HA. Bone density at the defect site rose from 682 HU at four weeks to 1,040 HU at sixteen weeks. Over the same window, autograft sites declined from 1,670 HU to 1,270 HU, and PLGA/HA showed no further bone growth after four weeks. By sixteen weeks there was no statistically significant difference between the polymer and autograft.

Koleva et al., BioResearch Open Access

Foot & ankle limb salvage

A 58-year-old patient presented with first metatarsal pseudarthrosis and chronic pain after four failed fusion procedures and a broken plate. Amputation was under consideration. The polymer was mixed with autologous bone marrow aspirate and delivered through an 8-gauge needle under fluoroscopic guidance, with no instrumentation and no reduction, in an outpatient setting. The patient went on to radiographic fusion.

Scarpone & Lee, case report

Biocompatibility

Evaluated across the ISO 10993 series. Results found no histological or genomic evidence of local or systemic toxicity, and characterized the material as non-irritating, non-toxic, and non-sensitizing.

ISO 10993 series

L3-S1 posterior instrumented fusion radiographs at 13 months, bony fusion annotated

L3–S1 posterior instrumented fusion at 13 months postoperatively; bony fusion annotated with arrows. Because the polymer is radiolucent on implantation, new bone formation is visible in real time on radiograph or CT, without the interference of radiopaque or mineralized graft substitutes. Kim et al., Bioengineering 2025;12:243 (CC BY 4.0).

Looking for the clinical literature behind this technology? Visit Clinical Resources for supporting studies and citations.

Ask About This Product See the Full Catalog